Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T22:12:19.046Z.
Calculation as of: 2026-10-06T22:12:19.046Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2a84589f7b73c5fc7448e1a11526b61c4e763dd9c6e5f877a8586f943b51ec8b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Inovio Pharmaceuticals, Inc.
Market Cap
$78.07M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$78.29M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$78.59M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$77.54M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$79.03M
Operating Cash Flow Yield
N/A
TTM Avg
0.15%
3Y Avg
0.15%
5Y Avg
0.15%
Market Cap
$76.74M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$79.61M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$75.95M
Operating Cash Flow Yield
28.92%
TTM Avg
26.53%
3Y Avg
15.21%
5Y Avg
15.21%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inovio Pharmaceuticals, Inc. (INO) | $78.07M | N/A | N/A | N/A | N/A |
| Sera Prognostics, Inc. (SERA)vs › | $78.29M | N/A | N/A | N/A | N/A |
| vTv Therapeutics Inc. (VTVT)vs › | $78.59M | N/A | N/A | N/A | N/A |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $77.54M | N/A | N/A | N/A | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $79.03M | N/A | 0.15% | 0.15% | 0.15% |
| Outset Medical, Inc. (OM)vs › | $76.74M | N/A | N/A | N/A | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $79.61M | N/A | N/A | N/A | N/A |
| SkinHealth Systems Inc. (SKIN)vs › | $75.95M | 28.92% | 26.53% | 15.21% | 15.21% |
| Humacyte, Inc. (HUMA)vs › | $80.30M | N/A | N/A | N/A | N/A |
| Pulmonx Corporation (LUNG)vs › | $75.18M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
